News: Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

86.63USD
17 Oct 2014
Price Change (% chg)

$1.61 (+1.89%)
Prev Close
$85.02
Open
$86.54
Day's High
$87.24
Day's Low
$86.05
Volume
434,919
Avg. Vol
300,948
52-wk High
$95.38
52-wk Low
$74.57

Search Stocks
Select another date:

Thu, Oct 16 2014

Novartis psoriasis drug benefits outweighs risk-FDA staff

- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

UPDATE 1-Novartis psoriasis drug benefits outweighs risk-FDA staff

Oct 16 - The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

Benefits of Novartis psoriasis drug outweighs risk: FDA staff

Oct 16 - The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

BUZZ-Oxford Biomedica: Signs 3-year deal with Novartis

** Oxford Biomedica's shares rise more than 20 pct after the gene-and-cell-based therapeutics maker says it has signed a three-year contract with Novartis AG that could bring in up to $90 million for the British company.

BRIEF-Oxford Biomedica signs further contract with Novartis for LentiVector

* Oxford Biomedica announces new process development and manufacturing collaboration which includes lentivector  licence agreement

Novartis employee pleaded guilty in Polish bribery case

ZURICH - An executive at a pharmaceutical company in Poland who pleaded guilty in a bribery case involving improper payment, works for Novartis, the Swiss drugmaker said on Thursday.

Novartis employee pleaded guilty in Polish bribery case

ZURICH, Oct 9 - An executive at a pharmaceutical company in Poland who pleaded guilty in a bribery case involving improper payment, works for Novartis, the Swiss drugmaker said on Thursday.

Amgen's Humira copy succeeds in skin disease trial

- Amgen Inc said its copycat version of AbbVie Inc's blockbuster biotech drug Humira showed comparable safety and ability to generate immune response in patients with a type of skin disease.

UPDATE 1-Amgen's Humira copy succeeds in skin disease trial

Oct 8 - Amgen Inc said its copycat version of AbbVie Inc's blockbuster biotech drug Humira showed comparable safety and ability to generate immune response in patients with a type of skin disease.

Shareholder group critical as Roche and Novartis chiefs top Swiss pay table

ZURICH - The bosses of drugmakers Roche and Novartis both earned more than 13 million Swiss francs ($13.6 million) last year, according to a study published on Wednesday, 18 months after the Swiss voted for some of the world's strictest controls on executive pay.

Select another date:
Search Stocks